1.88 USD
↗ 0.33 (21.29%)AT CLOSE (03:59 PM EST)
GRI Bio, Inc. Common Stock
GRINASDAQ • USD
1.88
↗ 0.01 (0.27%)
POST MARKET (AS OF 04:12 PM EST)
Post Market
AS OF 04:12 PM EST
1.88
↗ 0.01 (0.27%)
Market: CLOSED
GRI Bio, Inc. Common Stock (GRI) trades at $1.88 per share. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation side, GRI appears attractively valued relative to sector peers across key multiples.
Technical & fundamental data as of Nov 6, 2026.
Open?$1.56
High?$1.94
Low?$1.56
Prev. Close?$1.55
Volume?43.9K
Avg. Volume?46.3K
VWAP?$1.75
Rel. Volume?0.95x
Bid / Ask
Bid?$1.78 × 100
Ask?$1.96 × 100
Spread?$0.18
Midpoint?$1.87
Valuation & Ratios
Market Cap?4.1M
Shares Out?2.2M
Float?2.2M
Float %?99.4%
P/E Ratio?N/A
P/B Ratio?0.40
EPS?-$4.42
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Address
2223 AVENIDA DE LA PLAYA
LA JOLLA, CA 92037
Phone: (619) 400-1171
LA JOLLA, CA 92037
Phone: (619) 400-1171
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?75
Piotroski F-Score?0/9Weak
Altman Z-Score?-6.29Distress
Confidence?45%Low
Short InterestLow
Short % of Float?3.04%Low
Short Interest?66.1K
Days to Cover?1.6
Free Float2.2M
Avg Daily Volume40.8K
Settlement Date2026-10-15
Financial Health
Current Ratio?10.30Strong
Quick Ratio?10.30Strong
Cash Ratio?9.95Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.40CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?0.7CHEAP▾
Peers100
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-94.0%WEAK▾
S&P3
ROA?-84.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-10418000
Enterprise Value?$-6837104
Fundamentals ratios updated end of day